CRS stands for cytokine release syndrome, a potentially serious inflammatory reaction that happens when the immune system becomes massively activated, usually as a side effect of certain cancer treatments. It ranges from mild flu-like symptoms to a life-threatening emergency involving organ failure, and it occurs in 57% to 93% of patients receiving some of the newest immunotherapies.
How CRS Works in the Body
Cytokine release syndrome starts with a chain reaction inside the immune system. Treatments like CAR T-cell therapy are designed to supercharge immune cells so they attack cancer. But when large numbers of T cells, natural killer cells, and other immune cells all activate at once, they flood the bloodstream with signaling proteins called cytokines. These cytokines are normally part of a healthy immune response, helping coordinate the body’s defenses. The problem in CRS is one of scale: the release is so massive and so rapid that it triggers widespread inflammation throughout the body rather than a targeted response at one site.
One of the earliest cytokines released kicks off a cascade that causes blood vessels to widen and leak, body temperature to spike, and blood pressure to drop. Activated T cells then release additional inflammatory signals that amplify the response even further. Left unchecked, this escalating loop of immune activation can damage organs that were never the intended target of treatment.
Treatments That Trigger CRS
CRS was first described in the late 1980s when doctors observed it in transplant patients receiving a specific antibody-based drug to prevent organ rejection. Today it is most closely associated with newer immunotherapies used to treat blood cancers:
- CAR T-cell therapy: Genetically engineered immune cells are infused back into the patient to hunt cancer cells. CRS occurs in 57% to 93% of these patients, making it the most common serious side effect of this treatment.
- Bispecific antibodies: Lab-made proteins that physically bridge a patient’s T cells to cancer cells, forcing an immune attack. Clinical trials of newer versions report CRS rates as high as 51% to 89%.
- Stem cell transplants: Certain types of donor transplants can also trigger the syndrome, though less predictably.
Symptoms From Mild to Severe
The hallmark sign of CRS is fever, defined as a temperature at or above 38°C (100.4°F). In mild cases, the experience resembles a bad flu: fatigue, headache, muscle and joint aches, rash, and sometimes a cough. Many patients describe feeling generally unwell with chills and rapid breathing.
As CRS worsens, high fevers combine with dropping blood pressure. Breathing becomes more difficult, and some patients develop fluid buildup in the lungs. In its most severe form, CRS can cause circulatory shock requiring medications to maintain blood pressure, kidney failure, reduced heart function, and a dangerous widespread clotting disorder. Fluid can leak from blood vessels into surrounding tissue, causing swelling throughout the body. Acute respiratory distress, where the lungs fill with fluid and can no longer deliver enough oxygen, is one of the most dangerous complications.
How Severity Is Graded
Doctors use a standardized four-tier grading system published by the American Society for Transplantation and Cellular Therapy (ASTCT) in 2019. The grades are determined by three factors: fever, blood pressure, and oxygen needs.
- Grade 1: Fever only. No blood pressure problems, no need for supplemental oxygen.
- Grade 2: Fever plus low blood pressure that improves with fluids alone (no blood pressure medications needed), or a need for low-flow supplemental oxygen.
- Grade 3: Fever plus blood pressure low enough to require medication to maintain it, or a need for high-flow oxygen delivery such as a face mask.
- Grade 4: Fever plus blood pressure requiring multiple medications to maintain, or the need for mechanical breathing support.
The grade is always set by whichever symptom, low blood pressure or low oxygen, is more severe. So a patient with mild oxygen needs but dangerously low blood pressure would be classified at the higher grade. Once a patient receives treatment to control the syndrome, fever is no longer required for grading; the assessment shifts entirely to blood pressure and oxygen status.
Who Is at Higher Risk
Not everyone undergoing immunotherapy develops CRS at the same severity. The single biggest predictor is tumor burden, meaning how much cancer is present in the body at the time of treatment. This makes intuitive sense: more cancer cells mean more targets for the activated immune cells, which means a larger and more intense immune reaction.
Research on patients with acute lymphoblastic leukemia found that those with more than 22% cancer cells in their bone marrow before treatment had a significantly higher risk of severe CRS. For lymphoma patients, advanced-stage disease (particularly stage IV) was an independent risk factor. In multiple myeloma, the number of abnormal plasma cells in the bone marrow predicted CRS severity. Certain blood markers that track inflammation also climb steeply in patients heading toward worse reactions, giving medical teams early warning signs to watch for.
How CRS Is Treated
Mild CRS (grade 1) is typically managed with fever reducers and close monitoring. When symptoms escalate, the primary treatment is an intravenous medication called tocilizumab, which is FDA-approved specifically for severe or life-threatening CRS caused by CAR T-cell therapy in patients aged two and older. It works by blocking one of the key inflammatory signals driving the cascade. This drug can be given alone or combined with high-dose corticosteroids, which broadly suppress immune activity.
The goal of treatment is to interrupt the inflammatory spiral without completely undoing the cancer-fighting benefits of the therapy that triggered it. This is a delicate balance: the same immune activation causing CRS is also what destroys cancer cells. Medical teams in specialized centers monitor patients continuously after immunotherapy infusions, watching vital signs and blood markers so they can intervene quickly if CRS develops.
CRS and Neurological Side Effects
A related but distinct complication called ICANS (immune effector cell-associated neurotoxicity syndrome) can occur alongside CRS. While CRS affects the whole body, ICANS specifically targets the nervous system, causing symptoms like confusion, difficulty speaking, tremors, impaired consciousness, and in rare cases, seizures.
CRS typically appears first, and ICANS follows. The two conditions overlap in timing, and severe ICANS rarely occurs without severe CRS preceding it. The likely mechanism involves the same inflammatory proteins breaching the blood-brain barrier, the protective layer that normally shields the brain from substances circulating in the bloodstream. Once inflammatory cytokines reach the brain and spinal fluid in high concentrations, neurological symptoms develop. Patients with severe ICANS also tend to show signs of blood vessel dysfunction, including fluid leaking from capillaries and abnormal clotting.
Recovery Timeline
For most patients with mild CRS, symptoms resolve within about five days. Research distinguishing patients whose grade 1 CRS lasted fewer than five days from those whose symptoms persisted longer found meaningful differences in recovery. Patients with longer-lasting CRS, even at a low grade, had higher rates of prolonged low blood cell counts afterward, including extended periods of low white blood cells, red blood cells, and platelets. Elevated inflammation markers lasting ten days or more also predicted slower recovery of normal blood counts.
This means the duration of CRS matters, not just how severe it gets at its peak. Patients whose symptoms clear quickly tend to bounce back faster overall, while those with lingering inflammation face a longer road to full blood count recovery after treatment.